PL339371A1 - Composition containing 5-ht reuptake inhibitor and antagonist or partial agonist of h5-ht 1b - Google Patents
Composition containing 5-ht reuptake inhibitor and antagonist or partial agonist of h5-ht 1bInfo
- Publication number
- PL339371A1 PL339371A1 PL98339371A PL33937198A PL339371A1 PL 339371 A1 PL339371 A1 PL 339371A1 PL 98339371 A PL98339371 A PL 98339371A PL 33937198 A PL33937198 A PL 33937198A PL 339371 A1 PL339371 A1 PL 339371A1
- Authority
- PL
- Poland
- Prior art keywords
- antagonist
- composition containing
- reuptake inhibitor
- partial agonist
- agonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000004031 partial agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Replacement Of Web Rolls (AREA)
- Winding, Rewinding, Material Storage Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703375A SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | A new combination |
| PCT/SE1998/001601 WO1999013877A1 (en) | 1997-09-18 | 1998-09-09 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL339371A1 true PL339371A1 (en) | 2000-12-18 |
Family
ID=20408295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98339371A PL339371A1 (en) | 1997-09-18 | 1998-09-09 | Composition containing 5-ht reuptake inhibitor and antagonist or partial agonist of h5-ht 1b |
Country Status (29)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| WO2002066454A1 (fr) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| CA2445843A1 (en) * | 2001-05-01 | 2002-11-07 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
| US7504395B2 (en) * | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
| AR047553A1 (es) | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| KR100511288B1 (ko) * | 2003-11-14 | 2005-08-31 | 엘지전자 주식회사 | 4대의 압축기를 구비한 공기조화기의 실외기 |
| US20060217394A1 (en) * | 2005-02-23 | 2006-09-28 | Silvan S. Tomkins Institute, Inc. | Treatment of anhedonia |
| CA2617546C (en) | 2005-08-03 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
| FR2890862B1 (fr) * | 2005-09-19 | 2008-01-25 | Sanofi Aventis Sa | Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique. |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| RU2477634C2 (ru) * | 2006-06-16 | 2013-03-20 | Теракос, Инк. | Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| WO2008000760A1 (en) | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| WO2008022932A2 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| ES2162792T3 (es) * | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| SE9703374D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
-
1997
- 1997-09-18 SE SE9703375A patent/SE9703375D0/xx unknown
-
1998
- 1998-08-27 ZA ZA987817A patent/ZA987817B/xx unknown
- 1998-08-29 TW TW087114344A patent/TW589183B/zh not_active IP Right Cessation
- 1998-09-09 NZ NZ503171A patent/NZ503171A/en unknown
- 1998-09-09 DK DK98944375T patent/DK1014985T3/da active
- 1998-09-09 EE EEP200000141A patent/EE04141B1/xx not_active IP Right Cessation
- 1998-09-09 PT PT98944375T patent/PT1014985E/pt unknown
- 1998-09-09 ES ES98944375T patent/ES2200370T3/es not_active Expired - Lifetime
- 1998-09-09 IL IL13477698A patent/IL134776A0/xx unknown
- 1998-09-09 TR TR2000/00727T patent/TR200000727T2/xx unknown
- 1998-09-09 PL PL98339371A patent/PL339371A1/xx unknown
- 1998-09-09 AU AU91930/98A patent/AU752722B2/en not_active Ceased
- 1998-09-09 CN CNB98811206XA patent/CN1195519C/zh not_active Expired - Fee Related
- 1998-09-09 DE DE69814882T patent/DE69814882T2/de not_active Expired - Fee Related
- 1998-09-09 EP EP98944375A patent/EP1014985B1/en not_active Expired - Lifetime
- 1998-09-09 BR BR9812088-3A patent/BR9812088A/pt not_active IP Right Cessation
- 1998-09-09 RU RU2000109563/14A patent/RU2214824C2/ru not_active IP Right Cessation
- 1998-09-09 KR KR1020007002822A patent/KR20010024076A/ko not_active Ceased
- 1998-09-09 SK SK285-2000A patent/SK2852000A3/sk unknown
- 1998-09-09 AT AT98944375T patent/ATE240733T1/de not_active IP Right Cessation
- 1998-09-09 WO PCT/SE1998/001601 patent/WO1999013877A1/en not_active Ceased
- 1998-09-09 HU HU0200602A patent/HUP0200602A3/hu unknown
- 1998-09-09 JP JP2000511499A patent/JP2001516718A/ja active Pending
- 1998-09-09 US US09/171,580 patent/US6159971A/en not_active Expired - Fee Related
- 1998-09-09 CA CA002302382A patent/CA2302382A1/en not_active Abandoned
- 1998-09-16 MY MYPI98004225A patent/MY116280A/en unknown
- 1998-09-17 AR ARP980104634A patent/AR015448A1/es unknown
-
2000
- 2000-03-15 IS IS5406A patent/IS5406A/is unknown
- 2000-03-17 NO NO20001399A patent/NO20001399L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0200602A3 (en) | Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use | |
| ID17316A (id) | Komposisi aditif untuk pembawa bahan bermanfaat dan komposisi batang yang mengandung aditif tersebut | |
| ZA9810217B (en) | New composition of matter | |
| HUP9702036A3 (en) | Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them | |
| HUP9702035A3 (en) | Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them | |
| HUP9702034A3 (en) | Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them | |
| MX220980B (en) | Cementing compositions and use of such compositions for cementing oil wells or the like | |
| ZA9711437B (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
| CY2242B1 (en) | Benzonitriles and -fluorides as 5-ht agonists and antagonists | |
| ATE270889T1 (de) | Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung | |
| PL339619A1 (en) | Compositions containing copolymers of polyphenoles and method of obtaining such compositions | |
| AU4231699A (en) | Inhibitors of serotonin reuptake | |
| ZA977619B (en) | Naphthyl compounds intermediates compositions and methods of use | |
| PL339370A1 (en) | Composition containing selective antagonist of 5-ht 1a and selective antagonist or partial agonist of h5-ht 1b | |
| HUP0003832A3 (en) | Azeotropic or pseudo-azeotropic compositions and use of these compositions | |
| EP0914815A4 (en) | COMPOSITION FOR EXTERNAL USE FOR PREVENTING ENVIRONMENTAL STRESS | |
| AU8492398A (en) | Telomere mimetic compounds and methods of use for same | |
| SI1014985T1 (en) | A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist | |
| AU2221400A (en) | Compositions containing and methods of using n-acyl-1h-aminoindenes | |
| GB9820554D0 (en) | Use of cationic materials and compositions | |
| EP1100432A4 (en) | NEW APPLICATIONS OF ASCORBYL-PHOSPHORYL-CHOLESTEROL AND PREPARATIONS TO IMPLEMENT THEM | |
| BR9700132A (pt) | Composição contendo aditivos e coadjuvantes para a preservação de bebidas | |
| LT97046A (en) | Composition of aperitive ingredients | |
| LT97045A (en) | Composition of aperitive ingredients | |
| HK1032738A (en) | A combination of a monoamine oxidase inhibitor and a h5-ht 1 beta antagonist or partial agonist |